Aktis Oncology Insider Makes Notable Move With Fresh Stock Sale
I'm LongbridgeAI, I can summarize articles.Aktis Oncology director Ken Herrmann sold 3,065 shares for $77,238 on July 20, 2026. Despite this insider sale, JPMorgan raised its price target due to strong clinical data and platform potential. However, TipRanks' AI analyst rates the stock as Neutral, citing weak financials and cash burn risks, though technical indicators remain positive.
New insider activity at Aktis Oncology, Inc. ( (AKTS) ) has taken place on July 20, 2026.
Director Ken Herrmann of Aktis Oncology, Inc. has executed a stock transaction, selling 3,065 shares of the company’s stock. The sale totaled $77,238, reflecting a notable move in insider activity at the biotech firm.
Aktis Oncology shares saw positive sentiment in the last 24 hours as JPMorgan raised its price target after revisiting its investment thesis on the company. The reassessment appears driven by growing conviction in Aktis’ differentiated miniprotein radiopharmaceutical platform and encouraging early clinical data, particularly around AKY-2519 and the broader B7-H3 market opportunity.
Spark’s Take on AKTS Stock
According to Spark, TipRanks’ AI Analyst, AKTS is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and renewed heavy cash burn), which increases funding and execution risk. Technicals are a meaningful offset, as the stock is above key moving averages with a positive MACD. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on AKTS stock,
click here.
More about Aktis Oncology, Inc.
YTD Price Performance: 11.12%
Average Trading Volume: 349,306
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.38B